Get the Stockscreener App
2.937
1.95%
-0.133
After Hours:
2.93
-0.007
-0.24%
Marker Therapeutics Inc stock is traded at $2.937, with a volume of 35,427.
It is down -1.95% in the last 24 hours and down -14.49% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
See More
Previous Close:
$3.07
Open:
$3.14
24h Volume:
35,427
Relative Volume:
1.01
Market Cap:
$27.30M
Revenue:
-
Net Income/Loss:
$-8.24M
P/E Ratio:
-1.8827
EPS:
-1.56
Net Cash Flow:
$-16.44M
1W Performance:
-20.58%
1M Performance:
-14.49%
6M Performance:
-27.47%
1Y Performance:
+5.61%
1-Day Range:
$2.8205
$3.25
1-Week Range:
$2.8205
$3.90
52-Week Range:
$2.4377
$6.1568
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MRKR | 2.937 | 27.30M | 0 | -8.24M | -16.44M | -1.56 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Silence Therapeutics' Zerlasiran Shows 90% Reduction in Key Heart Disease Marker | SLN Stock News - StockTitan
Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Precision Optics Receives Initial Production Order for Single-Use Ophthalmic Program - The Manila Times
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Marker Therapeutics Secures $4M NIH Grants, Reports Promising MT-601 Trial Progress | MRKR Stock News - StockTitan
Alterity's Advanced Brain Imaging Breakthrough Reveals New MSA Disease Progression Marker | ATHE Stock News - StockTitan
Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma - OncLive
MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors - OncLive
US Penny Stocks To Consider In October 2024 - Simply Wall St
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts
Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK
Omega Therapeutics stock hits 52-week low at $1.2 - Investing.com
AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance
Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World
Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS
ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning - OncLive
Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech
Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily
Hematopoietic stem cell transplantation (HSCT) Market to See - openPR
Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool
Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show
Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors - OncLive
Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World
United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire
Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World
VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World
MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World
Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World
Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance
Raymond James & Associates Has $10.59 Million Stock Holdings in InvescoBulletShares2033 Corporate Bond ETF (NASDAQ:BSCX) - Defense World
Gene and Cell Therapy: Shaping the Future of Medicine - OncLive
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):